Given that the pharmacologic action of asunercept is mediated via binding to CD95L on the surface of glioblastoma cells, there are two major points to consider: the extravasation of asunercept via the blood-brain barrier (BBB) and the function of CD95L on the tumor cells. Here, FASLG is linked to glioblastoma.